SpringWorks Therapeutics Expects Ogsiveo Revenue To Be $61.5 Mln For Q4

(RTTNews) - SpringWorks Therapeutics, Inc. (SWTX) Monday said its expects revenue for the fourth quarter from its only approved product Ogsiveo to be $61.5 million.

Ogsiveo net product revenues were $5.4 million in the fourth quarter of 2023, the first partial quarter of the U.S. launch.

For the full year, the company sees product revenue of $172 million.

The company also provided priorities and anticipated milestones in 2025 including:

Secure regulatory approval for Ogsiveo in the EU; Report initial data from the Phase 2 study evaluating Ogsiveo in patients with ovarian granulosa cell tumors in the first half of 2025; Secure FDA approval for mirdametinib in patients with NF1-associated plexiform neurofibromas or NF1-PN and launch. A decision from the regulator is expected on February 28, 2025; Obtain regulatory approval in the EU for mirdametinib for the treatment of NF1-PN and begin initial launch in 2025. The company also expects to report data from its early stage studies of drug candidates in 2025.